^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD30-targeted antibody-drug conjugate

    Related drugs:
    8d
    NCI-2022-03831: Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides (clinicaltrials.gov)
    P2, N=30, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule)
    |
    TNFRSF8 expression
    |
    Adcetris (brentuximab vedotin)
    8d
    A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers (clinicaltrials.gov)
    P1, N=22, Completed, Seagen, a wholly owned subsidiary of Pfizer | Active, not recruiting --> Completed
    Trial completion
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    11d
    Brentuximab Vedotin in Advanced-Stage Mycosis Fungoides/Sézary Syndrome with Low CD30 Expression: Real-World Data from the German Cutaneous Lymphoma Network. (PubMed, Cancers (Basel))
    While response rates were similar, PFS was shorter. These findings suggest that BV remains a potential therapeutic option in this patient population and merits further prospective investigation.
    Journal • Real-world evidence
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    Adcetris (brentuximab vedotin)
    27d
    Prognostic and immunomodulatory roles of CD30 in diffuse large B-cell lymphoma: a cell-of-origin- and microenvironment-dependent paradigm. (PubMed, J Clin Exp Hematop)
    This understanding provides a strong rationale for COO- and TME-guided therapeutic strategies, such as combining the anti-CD30 antibody-drug conjugate brentuximab vedotin with immunomodulatory agents. This report elucidates the enigma of CD30 and outlines a path towards personalized medicine for DLBCL.
    Review • Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule)
    |
    TNFRSF8 expression
    |
    Adcetris (brentuximab vedotin)
    1m
    ECHELON-3: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL (clinicaltrials.gov)
    P3, N=238, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Nov 2025 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • lenalidomide • Adcetris (brentuximab vedotin)
    1m
    PA26 Folliculotropic mycosis fungoides with large cell transformation in an adolescent patient. (PubMed, Br J Dermatol)
    He commenced first-line systemic therapy with methotrexate, but had no response. He was switched to brentuximab vedotin and has received eight cycles with partial response...Approach to mycosis fungoides in children: consensus-based recommendations. J Am Acad Dermatol 2024; 91: 1078-85).
    Journal
    |
    CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule) • CD7 (CD7 Molecule) • SESN1 (Sestrin 1)
    |
    TNFRSF8 expression
    |
    methotrexate • Adcetris (brentuximab vedotin)
    2ms
    BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas (clinicaltrials.gov)
    P3, N=114, Enrolling by invitation, N.N. Petrov National Medical Research Center of Oncology
    New P3 trial
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • vincristine • prednisone
    2ms
    Developing a 3D Model Culture of an EBV+/CD30+ B-Anaplastic Large Cell Lymphoma Cell Line to Assay Brentuximab Vedotin Treatment. (PubMed, Antibodies (Basel))
    This simple and reproducible method of generating D430B-ALCL spheroids to evaluate their response to Brentuximab Vedotin treatment, as here described, may provide a valuable preliminary tool for the future pre-clinical screening of patients' primary lymphoma cells or the development of novel therapies for this type of pathology and related diseases.
    Preclinical • Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    Rituxan (rituximab) • Adcetris (brentuximab vedotin)
    2ms
    Real-life Efficacy and Toxicity of Brentuximab-Vedotin Associated With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL-R2-B2) (clinicaltrials.gov)
    P=N/A, N=222, Completed, University Hospital, Bordeaux | Not yet recruiting --> Completed | Initiation date: Sep 2025 --> Feb 2025
    Trial completion • Trial initiation date
    |
    Adcetris (brentuximab vedotin) • bendamustine
    2ms
    Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=45, Completed, University of Washington | Active, not recruiting --> Completed
    Trial completion
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    carboplatin • cyclophosphamide • ifosfamide • etoposide IV • Adcetris (brentuximab vedotin)
    2ms
    P30CA033572: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P2, N=48, Active, not recruiting, City of Hope Medical Center | Trial completion date: Aug 2025 --> Jul 2026
    Trial completion date
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive • TNFRSF8 positive • ALK negative
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • daunorubicin
    2ms
    KEYNOTE B81: Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors (clinicaltrials.gov)
    P2, N=161, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Dec 2029 --> Dec 2026 | Trial primary completion date: Dec 2029 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • BRAF mutation • ALK mutation
    |
    Keytruda (pembrolizumab) • Adcetris (brentuximab vedotin)